Doxorubicin + Cyclophosphamide, Then Docetaxel [clinicaltrials_resource:NCT00003782/group/E1]
Doxorubicin + Cyclophosphamide, then Docetaxel
Reported events for NCT00003782 [clinicaltrials_resource:944ce5d99abac83c0e226f24e94621c9]Total, other adverse events for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/58/count/172]Febrile neutropenia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/59/count/175]Diarrhea for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/60/count/178]Nausea for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/61/count/181]Vomiting for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/62/count/184]Fatigue for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/63/count/187]Infections and infestations - Other, specify for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/64/count/190]Arthralgia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/65/count/193]Myalgia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/66/count/196]Total, serious adverse events for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/1/count/1]Duodenal ulcer for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/10/count/28]Esophagitis for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/11/count/31]Gastrointestinal disorders - Other, specify for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/12/count/34]Mucositis oral for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/13/count/37]Typhlitis for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/14/count/40]Vomiting for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/15/count/43]General disorders and administration site conditions - Other, specify for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/16/count/46]Hepatic failure for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/17/count/49]Hepatobiliary disorders - Other, specify for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/18/count/52]Anaphylaxis for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/19/count/55]Febrile neutropenia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/2/count/4]Infections and infestations - Other, specify for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/20/count/58]Wound infection for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/21/count/61]Dermatitis radiation for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/22/count/64]Alanine aminotransferase increased (ALT/SGPT) for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/23/count/67]Aspartate aminotransferase increased (AST/SGOT) for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/24/count/70]Blood bilirubin increased for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/25/count/73]Creatinine increased for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/26/count/76]Neutrophil count decreased for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/27/count/79]White blood cell decreased for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/28/count/82]Anorexia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/29/count/85]Cardiac disorders - Other, specify for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/3/count/7]Dehydration for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/30/count/88]Hyperglycemia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/31/count/91]Hypertriglyceridemia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/32/count/94]Hypocalcemia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/33/count/97]Hypokalemia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/34/count/100]Hyponatremia for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/35/count/103]Musculoskeletal and connective tissue disorder - Other, specify for NCT00003782 for E1 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/36/count/106]
group [clinicaltrials_vocabulary:group]
Doxorubicin + Cyclophosphamide, Then Docetaxel [clinicaltrials_resource:NCT00003782/group/E1]
Doxorubicin + Cyclophosphamide, then Docetaxel
Bio2RDF identifier
NCT00003782/group/E1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00003782/group/E1
group id [clinicaltrials_vocabulary:group-id]
description
Doxorubicin + Cyclophosphamide, then Docetaxel
@en
identifier
clinicaltrials_resource:NCT00003782/group/E1
title
Doxorubicin + Cyclophosphamide, Then Docetaxel
@en
type
label
Doxorubicin + Cyclophosphamide ...... resource:NCT00003782/group/E1]
@en